Elaine, who's the AAT's Treasurer, joined the Board as Trustee in January 2018
Jane was appointed to the Board in April 2018
Jane is a communications expert and digital strategist with over 25 years’ experience. She currently serves as Head of Communications at Southern Housing Group, one of England's largest housing associations. She was previously Head of Digital Strategy at the Group. Jane has worked as a freelance consultant and her clients have included major international law firms, digital design agencies and advertising agencies. She has advised on brand, marketing and communications strategies, SEO and other digital communications strategies and specific product development, including traditional messaging and online content development.
Jane is a non-practising solicitor and an associate of the Chartered Institute of Marketing.
Martin joined the AAT's Board of Trustees in July 2018
Martin joined Wedlake Bell, a Top 100 Central London Law Firm in 1987 as a Trainee Solicitor.
Martin became a Partner in 1996 and was the head of the Insolvency and Restructuring team for 15 years.
In 2012 he became the Senior Partner of the firm and later that year the Managing Partner – a position he has held for six years.
Martin has been a long time supporter of the AAT:
Martin has also been a Trustee of a similarly small charity, the Richard and Jack Wiseman Trust, for over ten years and has been actively involved in its fundraising activities for the whole of that time.
Paul was Trustee of the Board between 2007-2014 and after a break re-joined in May 2017
Paul has worked in the construction industry for over 30 years, starting as a Quantity Surveyor. The past 21 years have been with ISG plc, a specialist international construction services provider operating in 21 countries and employing approx. 2800 people. Paul was appointed CEO of ISG in early 2016 when the company was privatised following a takeover by an American investor.Paul's commitment to the AAT is motivated by the fact his wife was diagnosed with Aplastic Anaemia in 1983. Initially Paul took part in several charity events organised by the AAT until in 2007 when he became a Trustee of the charity. Paul took a break from being a Trustee between late 2014 and early 2017 but has now recommitted for at least 3 more years.
Paul has been married for 28 years and has two grown up daughters. His hobbies include cycling, hiking and running, and he is a season ticket holder of Brentford FC.
Professor Peter Hillmen joins the AAT's Board of Trustees from the Haematology Team at St James' Hospital in Leeds
Peter leads the Experimental Haematology department at the Leeds Institute of Cancer and Pathology and the Translational Haematology Research Group. He is also an Honorary Consultant Haematologist at Leeds Teaching Hospitals NHS Trust.
Professor Hillmen qualified in Medicine at Leeds Medical School in 1985 and completed his general medical training in Leeds in 1988. He was a Haematology Registrar in Hammersmith Hospital, London between 1989 and 1990 before completing three years as a Wellcome Training Fellow based at the Royal Postgraduate Medical School (1991 to 1993) completing a PhD working on PNH under the supervision of Professor Lucio Luzzatto. He then moved back to Leeds as a Senior Registrar in Haematology, Yorkshire (1994 to 1996). He was appointed as a Consultant Haematologist Mid-Yorkshire Trust and Leeds General Infirmary in 1996 before moving to Leeds Teaching Hospitals NHS Trust in 2004. He was appointed as Professor of Experimental Haematology, University of Leeds in 2013.
Professor Hillmen has research interests in both paroxysmal nocturnal haemoglobinuria (PNH) and chronic lymphocytic leukaemia (CLL). Since 1990 he has continued to research into PNH that eventually led to the development of anti-complement therapy for PNH. He was the lead on the trials of eculizumab and now leads the National PNH Service based in Leeds and Kings. The National PNH service looks after over 300 patients with PNH and this provides a unique resource for continued research into the pathophysiology and therapy of PNH.
Professor Ted is founder Trustee and chaired the Board of Trustees between 2006-2017
Ted was instrumental in setting up a bone marrow transplantation unit at the Hammersmith Hospital in 1972, and launching the Marrow Environment Fund, with friends and family members of patients suffering from rare bone marrow failures. This grew into the Aplastic Anaemia Trust in the 90s, when Ted moved to St George’s to set up a department devoted to the bone marrow failure syndromes of which acquired Aplastic Anaemia was a particular but not exclusive interest. Fantastic advances have been made since then in understanding and treating acquired and constitutional AA. The AAT was hugely important in establishing the unit at St George’s and by engendering interest by the work in other units throughout the UK, has put the country at the forefront of research and treatment of these rare syndromes in the International community.
Ted is currently Emeritus Professor of Haematology, St George’s, University of London and Honorary Consultant Haematologist, St George’s NHS Trust, retired December 2013.
Professor Mufti joined the Board of Trustees in May 2017
Ghulam is the head of the department of haematological medicine at Guy’s, King’s and St Thomas’s hospitals, King’s College London, with a team of 13 professors, 6 senior lecturers/lecturers and approximately 100+ research staff. In addition, Professor Mufti is the Clinical Director of Laboratories Sciences and a non-executive director of King’s College Hospital NHS Foundation Trust.
Ghulam has extensive clinical and research expertise in leukaemias, lymphomas and in particular myelodysplastic syndromes, for which he is internationally renowned. His particular area of research has focused on molecular aberrations in MDS/AML and the identification of novel therapies that include gene and cell-based therapies. He has published 400+ papers and chapters in scientific journals and textbooks on leukaemias and MDS. He heads the research groups at King’s working on the molecular genetics of MDS/aplastic anaemia/AML and is a member of the working group that produced national and international guidelines on the treatment and prognosis of MDS. He is a member of the European Bone Marrow Transplantation Group and a founding member of the Board of the International Myelodysplastic foundation, for which his department at King’s College Hospital is a recognised Centre of Excellence. The department is also a centre of excellence for Leukaemia Lymphoma Research and is the largest allogeneic bone marrow transplant centre in the UK, and the only gene and cell-based therapies centre for myeloid leukaemia and allied diseases.
Professor Marsh joined the Board of Trustees in May 2017
Judith is a Professor of Clinical Haematology and Consultant Haematologist with specialist interest in aplastic anaemia disorders. She qualified from Birmingham University and prior to being appointed at King’s, worked at St George’s Hospital/ St George’s University of London as Professor of Clinical Haematology/Honorary Consultant Haematologist, Kingston University as visiting Professor.
Professor Marsh was Co-chairman of the Centre of International Blood and Marrow Transplant Research for nearly 10 years and currently chairs the writing board for British Committee for Standards in Haematology. Professor Marsh is Chairman of the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party and a member of the CIBMTR for International Affairs.
Sven became the Chair of the Board of Trustees in early 2017
Sven has worked in corporate finance and banking for 30 years in the UK, the US and in Germany. He was a trustee of the AAT from 2007 to 2014 and re-joined in early 2017. Sven supports the AAT as he was diagnosed with a related disease to AA, PNH, and was successfully treated at St George’s Hospital, London, by Professors Ted Gordon-Smith, Judith Marsh and their colleagues in 2001.
Sven has witnessed the AAT able to make a significant contribution to fighting the disease by funding research as well as easing the anxieties, concerns and worries of patients as they cope with the illness. He is committed to supporting the AAT to allow it to intensify its activities significantly by ensuring it has the structure to grow and to enhance its fund-raising capabilities.